Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 November 2017Website:
http://www.apellis.comNext earnings report:
05 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 21:29:55 GMTDividend
Analysts recommendations
Institutional Ownership
APLS Latest News
WALTHAM, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT study were presented as an oral presentation during the High-Impact Clinical Trials session at the American Society of Nephrology (ASN) Kidney Week. The results highlighted the strength of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, debilitating kidney diseases.
William Blair has initiated coverage on Apellis Pharmaceuticals, Inc. APLS and notes that Apellis was the first company to successfully target complement C3, which has led to the approval of two therapies: Empaveli (systemic pegcetacoplan) for paroxysmal nocturnal hemoglobinuria and Syfovre (intravitreal pegcetacoplan) for geographic atrophy secondary to age-related macular degeneration.
24/7 Wall St. Insights Here are some candidates to be the best-performing growth stock over the next five years.
Apellis Pharmaceuticals' Syfovre, despite initial safety concerns, shows strong revenue growth and is nearing profitability, making it a high-risk, high-reward investment. Syfovre's adjusted safety profile and bimonthly dosing offer advantages over Astellas' Izervay, though continued vigilance for retinal vasculitis is necessary. The Company's financial health is solid, with sufficient cash and assets to cover liabilities and fund operations until positive cash flow is achieved.
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) breached their fiduciary duties to shareholders.
APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.
WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed its June 2024 negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following September investor conferences:
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Meredith Kaya - SVP of IR & Strategic Finance Cedric Francois - Co-Founder & CEO Adam Townsend - COO Caroline Baumal - Chief Medical Officer Tim Sullivan - CFO Conference Call Participants Jonathan Miller - Evercore Anupam Rama - J.P. Morgan Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Colleen Kusy - Baird Phil Nadeau - TD Cowen Ivy Wang - Jefferies Eliana Merle - UBS Annabel Samimy - Stifel Francois Brisebois - Oppenheimer Douglas Tsao - H.C.
Apellis (APLS) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
What type of business is Apellis Pharmaceuticals?
Reata Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 2002. Based in the city of Plano, Texas, the company is involved in the development of new treatment methods based on the use of low molecular weight therapeutic agents with new mechanisms of action for the treatment of severe, life-threatening diseases. The main products of the company are bardoxolone methyl (a drug for the treatment of rare forms of chronic kidney disease (CKD)) and omaveloxolone (a drug for the treatment of rare neurological diseases). Both bardoxolone and omaveloxolone normalize mitochondrial function, restore redox balance, and eliminate inflammation. Since mitochondrial dysfunction, oxidative stress, and inflammation are features of many diseases, bardoxolone and omaveloxolone have a variety of potential clinical applications.
What sector is Apellis Pharmaceuticals in?
Apellis Pharmaceuticals is in the Healthcare sector
What industry is Apellis Pharmaceuticals in?
Apellis Pharmaceuticals is in the Biotechnology industry
What country is Apellis Pharmaceuticals from?
Apellis Pharmaceuticals is headquartered in United States
When did Apellis Pharmaceuticals go public?
Apellis Pharmaceuticals initial public offering (IPO) was on 09 November 2017
What is Apellis Pharmaceuticals website?
https://www.apellis.com
Is Apellis Pharmaceuticals in the S&P 500?
No, Apellis Pharmaceuticals is not included in the S&P 500 index
Is Apellis Pharmaceuticals in the NASDAQ 100?
No, Apellis Pharmaceuticals is not included in the NASDAQ 100 index
Is Apellis Pharmaceuticals in the Dow Jones?
No, Apellis Pharmaceuticals is not included in the Dow Jones index
When was Apellis Pharmaceuticals the previous earnings report?
No data
When does Apellis Pharmaceuticals earnings report?
The next expected earnings date for Apellis Pharmaceuticals is 05 November 2024